Samsung Biologics Offers $1.8 Billion for Swiss Peptide Manufacturer

A Strategic Push Into Peptide Therapeutics

Samsung Biologics has announced an all-cash tender offer valued at 1.46 billion Swiss francs ($1.81 billion) to acquire PolyPeptide, a Swiss contract manufacturer specializing in peptide-based drugs. The deal marks a significant expansion for the South Korean biotech company into one of the pharmaceutical industry's fastest-growing segments.

The offer price of 44.31 Swiss francs per share carries a 6.1 percent premium over PolyPeptide's closing price of 41.75 francs on the previous Friday. Both companies confirmed the transaction in separate statements, with the tender offer expected to launch by late August and conclude before year-end.

Capturing the GLP-1 Opportunity

The acquisition positions Samsung Biologics to capitalize on surging demand for peptide therapeutics, particularly GLP-1 drugs used to treat obesity and diabetes. These medications have become blockbusters in global pharmaceutical markets, with manufacturers struggling to meet demand as prescriptions multiply across developed economies.

PolyPeptide operates as a contract development and manufacturing organization, producing active pharmaceutical ingredients for peptide-based therapies on behalf of drug developers. The company's expertise in synthesizing complex peptide molecules makes it a valuable asset as pharmaceutical firms race to develop next-generation metabolic treatments.

For Samsung Biologics, the deal represents a natural extension beyond its core biologics manufacturing business. The company already operates some of the world's largest bioreactor facilities in Incheon, South Korea, supplying monoclonal antibodies and other biological drugs to global pharmaceutical clients.

Board Backing and Majority Shareholder Support

PolyPeptide's board has unanimously recommended that shareholders accept the offer. The Swiss company's largest shareholder, Draupnir Holding, which controls approximately 55.65 percent of outstanding shares, has committed to tendering its entire stake into the bid.

Draupnir announced in April that it was reviewing strategic options for its majority position in PolyPeptide. The holding company is controlled by the Cryosphere Foundation, an entity with ties to Swedish billionaire Frederik Paulsen, according to previous disclosures from PolyPeptide.

With majority shareholder support secured, Samsung Biologics faces minimal risk of a competing bid derailing the transaction. The South Korean company has stated its intention to pursue a squeeze-out of any remaining minority shares following completion of the tender offer, with plans to delist PolyPeptide from the SIX Swiss Exchange and operate it as a wholly owned subsidiary.

Asia's Growing Pharmaceutical Ambitions

The transaction reflects broader trends in Asian pharmaceutical investment, as companies from South Korea, China, and India seek to move up the value chain from generic manufacturing into specialized therapeutic areas. Samsung Biologics has emerged as a leading contract manufacturer for biologics, counting major Western pharmaceutical firms among its clients.

Acquiring PolyPeptide's peptide synthesis capabilities complements Samsung's existing biologics infrastructure, allowing the company to offer clients a broader range of manufacturing services. The deal also provides geographic diversification, with PolyPeptide operating production facilities in Europe that serve pharmaceutical customers across multiple regions.

The timing aligns with heightened investor interest in obesity therapeutics, a market segment projected to exceed $100 billion in annual sales within the next decade. Contract manufacturers with proven capabilities in producing GLP-1 drugs and similar peptide therapies command premium valuations as pharmaceutical companies outsource production to meet demand.

Samsung Biologics has not disclosed financing details for the acquisition, though the company maintains a strong balance sheet from its contract manufacturing operations. The transaction will require regulatory approvals in multiple jurisdictions, though such clearances are typically routine for deals involving contract manufacturers rather than drug developers with overlapping product portfolios.

The delisting of PolyPeptide from the Swiss exchange will remove one of the few publicly traded pure-play peptide manufacturers from European equity markets, consolidating the company under Samsung's ownership as the South Korean firm builds out its position in next-generation therapeutics.